Covid-19 roundup: With ef­fi­ca­cy da­ta in hand, BioN­Tech talks pric­ing; Brazil halts Sino­vac tri­al fol­low­ing pa­tient death

On the heels of be­com­ing the first to re­lease Phase III ef­fi­ca­cy da­ta for the Covid-19 vac­cine it de­vel­oped with Pfiz­er, BioN­Tech is now talk­ing pric­ing.

BioN­Tech CSO Ryan Richard­son said at a Fi­nan­cial Times vir­tu­al event that the com­pa­ny is aim­ing to set a price point be­low “typ­i­cal mar­ket rate” for its two-shot vac­cine, per Reuters. The firm al­so ex­pects the price will be dif­fer­ent de­pend­ing on the coun­try or re­gion in which it’s sold, though Richard­son did not elab­o­rate.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN